Aerie Pharmaceuticals Inc. (AERI)
$15.25
$0.00 (0.00%)As on 22-Nov-2022 09:30EDT
Market cap
$754 Mln
Revenue (TTM)
$214 Mln
P/E Ratio
--
P/B Ratio
34.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-37 Mln
-
ROE
-22.6 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-350.2
-
Debt to Equity
-1.9
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
49,417,400
10 Years Aggregate
CFO
$-760.79 Mln
EBITDA
$-920.11 Mln
Net Profit
$-1,102.85 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals Inc (AERI)
| 117.2 | 0.3 | 38.8 | 51.9 | -6.1 | -24.3 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals Inc (AERI)
| -48.0 | -44.1 | -33.0 | -39.4 | 57.9 | 55.4 | -16.6 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals Inc (AERI)
|
15.3 | 753.6 | 213.9 | -36.6 | -10.9 | -- | -- | 34.3 |
| 17.9 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 16.2 | 32.7 | 38.3 | 12.7 | |
| 208.4 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 75.4 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 112.8 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 24.4 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 289.7 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.6 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 128.7 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Aerie Pharmaceuticals Inc (AERI)
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the... United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina. Read more
-
CEO, Principal Financial Officer & Director
Mr. Raj Kannan
-
CEO, Principal Financial Officer & Director
Mr. Raj Kannan
-
Headquarters
Durham, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aerie Pharmaceuticals Inc (AERI)
What is the current share price of Aerie Pharmaceuticals Inc (AERI) Today?
The share price of Aerie Pharmaceuticals Inc (AERI) is $15.25 (NASDAQ) as of 22-Nov-2022 09:30 EDT. Aerie Pharmaceuticals Inc (AERI) has given a return of -6.07% in the last 3 years.
What is the current PB & PE ratio of Aerie Pharmaceuticals Inc (AERI)?
Since, TTM earnings of Aerie Pharmaceuticals Inc (AERI) is negative, P/E ratio is not available.
The P/B ratio of Aerie Pharmaceuticals Inc (AERI) is 34.26 times as on 02-Dec-2022, a 342 premium to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-4.32 |
-18.63 |
2020 |
-3.39 |
25.93 |
2019 |
-5.45 |
6.51 |
2018 |
-6.52 |
6.66 |
2017 |
-14.41 |
15.42 |
What is the 52 Week High and Low of Aerie Pharmaceuticals Inc (AERI)?
The 52-week high and low of Aerie Pharmaceuticals Inc (AERI) are Rs -- and Rs -- as of 04-Sep-2026.
What is the market cap of Aerie Pharmaceuticals Inc (AERI)?
Aerie Pharmaceuticals Inc (AERI) has a market capitalisation of $ 754 Mln as on 02-Dec-2022. As per SEBI classification, it is a company.
Should I invest in Aerie Pharmaceuticals Inc (AERI)?
Before investing in Aerie Pharmaceuticals Inc (AERI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.